Shun Lu
A Shanghai lung cancer trialist who has led many Chinese PD-1 and EGFR-TKI phase 3 studies.
Shun Lu has been principal investigator for Chinese phase 3 trials including sintilimab and tislelizumab combinations in NSCLC and for furmonertinib and other EGFR inhibitors.
Patients newly diagnosed with EGFR-mutated advanced lung cancer now have a first-line option that improves survival over osimertinib, particularly if they have high-risk features. The trade-off is intravenous (now subcutaneous) infusions and considerably more skin, nail and clotting toxicity, so osimertinib alone remains reasonable for those who prioritise convenience and tolerability. Both this regimen and osimertinib plus chemotherapy (FLAURA2) are approved; there is no direct comparison.
Patients with operable stage II-III lung cancer without EGFR or ALK alterations should have chemo-immunotherapy discussed before surgery rather than only afterwards. Three pre-operative cycles do not compromise the operation and improve cure rates. Whether to continue immunotherapy after surgery, as the perioperative trials do, and whether patients with pCR need any further treatment, remain open questions.
Every resected non-squamous lung cancer should be tested for EGFR mutations, because patients who carry one live longer if they take osimertinib for three years after surgery. The trial does not tell us whether adjuvant chemotherapy can be omitted, nor what happens on relapse after osimertinib, and the three-year duration was chosen empirically.
Pages like this
not linked directly; found by shared links- PersonEnriqueta Felip
Shares CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer, EGFR, Non-small-cell lung cancer.
- TrialRATIONALE-306
Shares Tislelizumab, PD-1.
- PersonPatrick M. Forde
Shares CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, PD-1, Non-small-cell lung cancer.
- PersonJulie R. Brahmer
Shares CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, PD-1, Non-small-cell lung cancer.
- PersonKumar Prabhash
Shares MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer, EGFR, Non-small-cell lung cancer.
- PersonJie He
Shares ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer, Non-small-cell lung cancer.
- PersonYi-Long Wu
Shares ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer, EGFR, Non-small-cell lung cancer.
- PersonJie Wang
Shares Tislelizumab, Non-small-cell lung cancer.